Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [2][17]. Core Views - The company plans to acquire 70% of Huilian Electronics for no more than 700 million yuan, and 70% of WINWIN HITECH (THAILAND) CO., LTD. for no more than 28 million yuan, marking its entry into the PCB drill needle sector [2]. - The acquisition is seen as a strategic move to enhance the company's product line in PCB specialized tools and to capitalize on high-growth areas driven by AI and advanced communication technologies [4][8]. - The report projects significant revenue growth, with total revenue expected to reach 2.612 billion yuan in 2025, 3.798 billion yuan in 2026, and 5.216 billion yuan in 2027, reflecting year-on-year growth rates of 40.3%, 45.4%, and 37.3% respectively [4][9]. - Net profit is forecasted to grow to 235 million yuan in 2025, 386 million yuan in 2026, and 515 million yuan in 2027, with corresponding growth rates of 30.3%, 63.8%, and 33.6% [4][9]. - The target price for the stock is set at 73.44 yuan, based on a projected PE ratio of 48 times for 2026 [4][8]. Financial Projections - Total revenue projections for 2024, 2025, 2026, and 2027 are 1.862 billion yuan, 2.612 billion yuan, 3.798 billion yuan, and 5.216 billion yuan respectively, with year-on-year growth rates of 20.2%, 40.3%, 45.4%, and 37.3% [4][9]. - The expected net profit for the same years is 180 million yuan, 235 million yuan, 386 million yuan, and 515 million yuan, with growth rates of 10.9%, 30.3%, 63.8%, and 33.6% [4][9]. - Earnings per share (EPS) are projected to be 0.72 yuan, 0.93 yuan, 1.53 yuan, and 2.04 yuan for the years 2024, 2025, 2026, and 2027 respectively [4][9].

证券研究报告：电子 | 公司点评报告 发布时间：2026-02-24 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 84.15 | | --- | --- | | 总股本/流通股本（亿股）1.70 | / 1.70 | | 总市值/流通市值（亿元）143 | / 143 | | 周内最高/最低价 52 | 106.78 / 19.30 | | 资产负债率(%) | 7.2% | | 市盈率 | 350.63 | | 第一大股东 | 更多亮照明有限公司 | 研究所 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 分析师:翟一梦 SAC 登记编号:S1340525040003 Email:zhaiyimeng@cnpsec.com 神工股份(688233) 硅材料到硅零部件一体化生产，充分受益存储扩产 l 投资要点 25Q4 收入大幅增长，具备较强业绩弹性。根据公司 2025 年业绩 预告，营收方面，预告范围为4.3-4.5亿元，同比增长42.04%-48.65%， 公司前三季度单季度平均收入约为 1 亿元（ ...

Investment Rating - The report assigns a rating of "Buy" to the company with a target price of 79.10 CNY, based on its strong position in the refrigerant market and expected growth in revenue and profit [5][20]. Core Insights - The company is a leader in the refrigerant industry, particularly in the production of third-generation refrigerants, which are expected to see price increases due to growing downstream demand and supply constraints from quota management [2][12]. - The financial outlook is positive, with projected revenue growth from 3,334 million CNY in 2023 to 7,295 million CNY by 2027, representing a compound annual growth rate (CAGR) of approximately 21.2% [4][18]. - The company is actively expanding its fluorine industry chain, with ongoing projects in lithium hexafluorophosphate and various fluoropolymer production lines, enhancing its integrated operations [12][36]. Financial Summary - Total revenue is expected to grow from 3,334 million CNY in 2023 to 7,295 million CNY by 2027, with a significant increase in net profit from 280 million CNY to 3,101 million CNY over the same period [4][18]. - The company’s net profit margin is projected to improve significantly, with net profit margins reaching 39.5% by 2026 [4][30]. - The earnings per share (EPS) is forecasted to rise from 0.46 CNY in 2023 to 5.08 CNY in 2027, indicating strong profitability growth [4][20]. Business Overview - The company specializes in fluorinated refrigerants, with a significant market share in HFCs, which are crucial for air conditioning and refrigeration systems [22][24]. - The production quotas for HFCs are set to be managed starting in 2024, which will likely lead to price increases due to limited supply [22][34]. - The company holds a leading position in HFC production capacity, with substantial quotas for HFC-134a, HFC-125, HFC-32, and HFC-143a, accounting for significant portions of national production quotas [24][25]. Market Trends - The demand for third-generation refrigerants is expected to remain strong, driven by growth in the home appliance and automotive sectors, with air conditioning production projected to increase from 210 million units in 2020 to 267 million units by 2025 [32][33]. - The average market price for R32 is anticipated to rise from 13,472 CNY per ton in early 2023 to 63,000 CNY per ton by early 2026, reflecting a 368% increase [34][35]. - The automotive air conditioning market for R134a is also expected to see significant price increases, from 23,500 CNY per ton to 58,000 CNY per ton over the same period, marking a 146.81% rise [34][35].

医药生物/化学制药 前沿生物（688221.SH） 两款 siRNA 管线独家授权 GSK，携手推进全球合作 2026 年 02 月 24 日 chaoshuran@kysec.cn 证书编号：S0790525110001 投资评级：买入（维持） | 日期 | 2026/2/13 | | --- | --- | | 当前股价(元) | 22.60 | | 一年最高最低(元) | 29.98/7.16 | | 总市值(亿元) | 84.65 | | 流通市值(亿元) | 84.65 | | 总股本(亿股) | 3.75 | | 流通股本(亿股) | 3.75 | | 近 3 个月换手率(%) | 252.45 | 股价走势图 数据来源：聚源 -50% 0% 50% 100% 150% 200% 2025-02 2025-06 2025-10 前沿生物 沪深300 相关研究报告 《补体管线研发稳步推进，FB7011 双 靶点头对头优效—公司信息更新报 告》-2025.10.31 《前瞻布局小核酸打开成长空间，HIV 用药稳增长—公司首次覆盖报告》 -2025.9.25 余汝意（分析师） 巢舒然（分析师） yuru ...

Investment Rating - The report assigns a rating of "Buy" to the company with a target price of 79.10 CNY, based on its strong position in the refrigerant market and expected growth in revenue and profit [5][20]. Core Insights - The company is a leader in the refrigerant industry, particularly in the production of third-generation refrigerants, which are expected to see price increases due to growing downstream demand and supply constraints from quota management [2][12]. - The financial outlook is positive, with projected revenue growth from 3.33 billion CNY in 2023 to 7.30 billion CNY by 2027, and net profit expected to rise from 280 million CNY to over 3.10 billion CNY in the same period [4][28]. Financial Summary - Total revenue is forecasted to grow significantly, with a compound annual growth rate (CAGR) of 46.2% from 2024 to 2025 [4]. - Net profit attributable to shareholders is expected to increase dramatically, with a forecast of 2.03 billion CNY in 2025, reflecting a growth rate of 161.3% compared to 2024 [4]. - The company’s earnings per share (EPS) is projected to rise from 0.46 CNY in 2023 to 5.08 CNY by 2027 [4]. Business Overview - The company specializes in fluorinated chemicals, with a significant focus on refrigerants, which are the main source of revenue and gross profit [22]. - The production capacity for key refrigerants such as HFC-134a, HFC-125, HFC-32, and HFC-143a is substantial, with the company holding a significant share of the national production quotas [24][25]. Market Trends - The price of R32 refrigerant is expected to rise from 13,472 CNY per ton in early 2023 to 63,000 CNY per ton by early 2026, marking an increase of 368% [34]. - The automotive air conditioning refrigerant R134a is projected to increase from 23,500 CNY per ton to 58,000 CNY per ton, a rise of 146.81% [34]. Strategic Initiatives - The company is actively expanding its production capabilities and enhancing its supply chain integration, with several projects underway, including lithium hexafluorophosphate and various fluoropolymer production lines [36][37]. - The company emphasizes research and development, holding 125 authorized patents and continuing to innovate in environmentally friendly products [37][39].

医药生物/化学制药 前沿生物（688221.SH） 两款 siRNA 管线独家授权 GSK，携手推进全球合作 2026 年 02 月 24 日 投资评级：买入（维持） | 日期 | 2026/2/13 | | --- | --- | | 当前股价(元) | 22.60 | | 一年最高最低(元) | 29.98/7.16 | | 总市值(亿元) | 84.65 | | 流通市值(亿元) | 84.65 | | 总股本(亿股) | 3.75 | | 流通股本(亿股) | 3.75 | | 近 3 个月换手率(%) | 252.45 | 股价走势图 数据来源：聚源 -50% 0% 50% 100% 150% 200% 2025-02 2025-06 2025-10 前沿生物 沪深300 相关研究报告 siRNA 管线方面，公司已有用于治疗 IgA 肾病的 FB7013（补体系统单靶点， 2025/12/31 国内 IND 申请获 CDE 受理）、FB7011（补体系统双靶点，IND enabling 阶段）；FB7023（治疗 ASCVD），已确定临床前候选分子（PCC），并启动了在 自发性高血脂猕猴模型上的药效 ...

2026 年 2 月 24 日 公司研究 AI 等需求拉动电子特气放量，25 年公司业绩稳健增长 ——中船特气（688146.SH）跟踪点评 增持（维持） 当前价：43.84 元 作者 分析师：赵乃迪 执业证书编号：S0930517050005 010-57378026 zhaond@ebscn.com 分析师：周家诺 执业证书编号：S0930523070007 021-52523675 zhoujianuo@ebscn.com 市场数据 | 总股本(亿股) | 5.29 | | --- | --- | | 总市值(亿元)： | 232.09 | | 一年最低/最高(元)： | 24.14/52.40 | | 近 3 月换手率： | 242.93% | 股价相对走势 -16% 4% 24% 44% 65% 02/25 05/25 08/25 11/25 中船特气 沪深300 收益表现 | % | 1M | 3M | 1Y | | --- | --- | --- | --- | | 相对 | -6.50 | 2.68 | 28.90 | | 绝对 | -7.49 | 7.45 | 46.30 | | 资料来源： ...

证券研究报告 | 首次覆盖报告 gszqdatemark 2026 02 24 年 月 日 行业：丁腈手套综合性能优异，需求持续景气。丁腈手套过敏率低，综合 性能表现优异，可应用于医疗、工业、民用等各类使用场景，渗透率持续 提升。据马来西亚丁腈手套龙头贺特佳，25 年全球橡胶手套需求约 3250- 3750 亿只，未来有望保持大单位数增长趋势。从供需结构来看，欧美需求 占比约 60%；供给则集中在中国和马来西亚，各占比 30%-40%。我们预 计在需求稳健增长、供给集中度提升的背景下，行业竞争将进一步回归成 本与效率。 核心壁垒：技术领先+原材料自供/燃煤优势+规模效应，成本优势突出。 丁腈手套行业竞争充分，成本优势为核心。公司通过技术、原材料、能源 及规模四个维度构筑难以复制的成本壁垒：① 产线新、自动化水平高， 生产效率持续领先；② 原材料与能源合计占成本约 6-7 成，其中公司核 心原材料丁腈胶乳自供比例达 80%，低于同业的外采依赖；同时公司为主 要全球手套厂商中少数以燃煤为主要能源结构的企业，较天然气或外购蒸 汽具备明显成本优势；③ 公司已成为全球最大的丁腈手套生产商，扩产 仍在推进，规模效应有望进 ...

证券研究报告：电子 | 公司点评报告 发布时间：2026-02-24 股票投资评级 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（元） | 84.15 | | --- | --- | | 总股本/流通股本（亿股）1.70 | / 1.70 | | 总市值/流通市值（亿元）143 | / 143 | | 周内最高/最低价 52 | 106.78 / 19.30 | | 资产负债率(%) | 7.2% | | 市盈率 | 350.63 | | 第一大股东 | 更多亮照明有限公司 | 研究所 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 分析师:翟一梦 SAC 登记编号:S1340525040003 Email:zhaiyimeng@cnpsec.com 硅材料到硅零部件一体化生产，充分受益存储扩产 l 投资要点 25Q4 收入大幅增长，具备较强业绩弹性。根据公司 2025 年业绩 预告，营收方面，预告范围为4.3-4.5亿元，同比增长42.04%-48.65%， 公司前三季度单季度平均收入约为 1 亿元（未经审计），第四季度收 入 ...

Investment Rating - The report maintains a "Buy" rating for the company [3][57]. Core Insights - The company is transitioning from a single-product model to a platform-based beverage giant, with energy drink sustainability and new product expansion being key factors influencing performance and stock price [8]. - The energy drink segment is expected to stabilize in the short term, with long-term growth potential remaining significant due to market expansion and increasing consumer demographics [11][14]. - New product launches, particularly in milk tea and unsweetened tea, are anticipated to catalyze sales growth in the upcoming months [18][23]. - Multiple internal and external factors are expected to contribute to margin improvement, including raw material cost reductions and operational efficiencies [29]. - The company is focusing on expanding its presence in Southeast Asia, with significant revenue potential projected for the region by 2030 [37]. Financial Forecasts - Revenue projections for 2025 to 2027 are estimated at 211 billion, 271 billion, and 330 billion CNY, respectively, with year-on-year growth rates of 33%, 28%, and 22% [48]. - The net profit for the same period is forecasted to be 45 billion, 59 billion, and 73 billion CNY, reflecting growth rates of 37%, 30%, and 23% [49]. - The company's price-to-earnings (PE) ratios are projected to be 33, 25, and 20 for the years 2025, 2026, and 2027, respectively, indicating a favorable valuation compared to industry peers [57].